Stentys raises $18 million in series B financing

Series A investor Sofinnova Partners also participated in the B round. Aelios Finance served as financial advisor to Stentys. Brian Kerr, one of the founding directors of Scottish Equity Partners and a partner in the firm’s Healthcare Group, will join the Stentys board of directors.

Gonzague Issenmann, CEO and co-founder of Stentys, said: “This financing round will allow us to complete clinical trials and obtain CE Mark for our drug-eluting, bifurcated stent, enabling interventional cardiologists to offer their patients the next generation of dedicated bifurcated-stenting procedures.”